Oragenics, Inc. (OGEN) saw a decrease of 3.38% in the premarket today after the company initiated the COVID-19 Challenge Study. The last trading session closed at $0.6441 with a downfall of 0.91%.
OGEN began COVID-19 Challenge Study
On 15th September 2021, the company announced the start of research to assess immunogenicity. The research will also cover the load reduction impact of its SARS-CoV-2 vaccine candidate. Firstly, the research will give information on a variety of vaccination formulations.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Secondly, the most promising formulations will be chosen based on cross-neutralization titers against the Wuhan, Beta, and Delta versions of COVID-19. It also causes a reduction in the viral load of the Wuhan challenge virus. Thirdly, the Company’s Canadian colleague is conducting the trial, with findings due in November.
OGEN’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice
On August 30, 2021, OGEN revealed that the stabilized pre-fusion spike protein trimer produces neutralizing antibodies. The expression platform, which Oragenics developed with the aid of a Canadian colleague, will speed up the testing of hybrid SARS-CoV-2 antigen candidates.
OGEN Signs a Licensing Contract
On July 27, 2021, Oragenics stated that it has signed a deal with Canada’s National Research Council (NRC) to investigate the rapid development of next-generation vaccines. Moreover, Oragenics now has a platform that can produce cell lines for the high-yield synthesis of spike protein antigens for existing and forthcoming variants of concern.
Also, Once the spike gene sequence is known, this method should allow cell lines to create in six to eight weeks. Thanks to supporting from the NRC’s Pandemic Response Challenge Program. The NRC’s technologies will speed up the examination of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
Management and Board of Directors Changes at OGEN
OGEN reports changes in administration and board of directors on May 3, 2021. On May 2, 2021, Dr. Alan Joslyn resigned as Oragenics, Inc.’s Chief Executive Officer to pursue other opportunities. In addition, the Board of Directors will lead the company until a new CEO comes. Lastly, Mr. Sullivan will act as interim primary executive officer to replace the position left vacant.